Recent Material Events - Acadia Pharmaceuticals, Inc (ACAD)

Filing Date	Description
2008-06-16	On June 16, 2008, ACADIA Pharmaceuticals Inc. issued a press release announcing top-line results from its Phase IIb trial with ACP-104 for the treatment of schizophrenia. The study did not meet its primary endpoint of antipsychotic efficacy or any of ...
2008-05-05	(d) On May 1, 2008, our Board of Directors elected Laura A. Brege as a director to fill an existing vacancy. We are not aware of any item requiring disclosure under Item 404(a) of Regulation S-K. ...
2007-03-19	The press release announced that ACADIA will hold a conference call and webcast today at 9:00 a.m. Eastern time to discuss the trial. A copy of the slides that will be presented on the webcast is attached hereto as Exhibit 99.2.... ...
2007-03-06	Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.... ...
2006-12-04	ACADIA Pharmaceuticals Inc. announced on December 4, 2006, that it has entered into a license agreement dated as of November 30, 2006 for certain intellectual property rights from the Ipsen Group in order to expand and strengthen the intellectual pro... ...
2006-11-06	Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.... ...
2006-10-23	The descriptions of the separation agreement and consultant agreement set forth above are qualified in their entirety by reference to the actual terms of the separation agreement and consultant agreement, which are filed as Exhibits 99.1 and 99.2, re... ...